SGLT2 inhibitors are linked with a lower risk of acute decompensated heart failure in humans (propensity-matched cohort) (mHR 0.578 (95% CI 0.34–0.99)).
Humanspropensity-matched cohortup to 3 yearsn = 620
SGLT2 inhibitors are linked with a lower risk of acute decompensated heart failure in propensity-matched patients with HFrEF and ESRD on dialysis (35.7% vs. 45.1%; risk difference -9.4%).
Humansin propensity-matched patients with HFrEF and ESRD on dialysis540-day follow-upn = 8,168
SGLT2 inhibitors are linked with a lower risk of acute decompensated heart failure in humans (HFpEF with ESRD, propensity-matched retrospective TriNetX cohort) (HR 0.72, 95% CI 0.67-0.77).
HumansHFpEF with ESRD, propensity-matched retrospective TriNetX cohort18 monthsn = 7,238
Acute decompensated heart failure is associated with physical function in humans (Short Physical Performance Battery score 5.3 ± 2.8; 6-minute walk distance 178 ± 102 m).
Humanshospitalized with acute decompensated heart failure; compared with age-matched stable heart failure and healthy cohortsn = 27
The program improved six-minute walking distance by an estimated 16.91 meters compared with routine care in a randomized trial of 174 hospitalized patients.The program improved six-minute walking distance by an estimated 16.91 meters compared with routine care in a randomized trial of 174 hospitalized patients.
Women in counties above 4 picocuries per liter had a heart failure hazard ratio of 1.19 versus those below 2 picocuries per liter.Women in counties above 4 picocuries per liter had a heart failure hazard ratio of 1.19 versus those below 2 picocuries per liter.
In older adults hospitalized for heart failure, rising markers were linked to 49.7 meters less improvement in six-minute walking distance over three months.In older adults hospitalized for heart failure, rising markers were linked to 49.7 meters less improvement in six-minute walking distance over three months.
Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.Thirty-day mortality was 2.9% among older patients discharged on all four recommended drug types, versus 19.1% among those prescribed three or fewer.
The adjusted hazard ratio, a measure of relative risk, was 1.64 for cardiovascular death or worsening heart failure over two months, comparing highest versus lowest…The adjusted hazard ratio, a measure of relative risk, was 1.64 for cardiovascular death or worsening heart failure over two months, comparing highest versus lowest blood-marker groups.